Vaxelis™
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Vaccines, Combined
Conditions
Vaccines, Combined, Hexavalent Vaccine
Trial Timeline
Mar 25, 2022 → Aug 30, 2022
NCT ID
NCT05289271About Vaxelis™
Vaxelis™ is a approved stage product being developed by Merck for Vaccines, Combined. The current trial status is completed. This product is registered under clinical trial identifier NCT05289271. Target conditions include Vaccines, Combined, Hexavalent Vaccine.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05289271 | Approved | Completed |
Competing Products
20 competing products in Vaccines, Combined